Objectives-To present the Scottish interval cancer data from 1991 to 1995, compare the Scottish experience with results published by other programmes and trials, and document appropriate methodologies to achieve maximum ascertainment of interval cancers. Setting-Scottish breast screening programme (part of the UK National Health Service breast screening programme). Methods-Interval cancers were identified by linking breast screening data with registrations of invasive breast cancers from the National Scottish Cancer Register. The main outcome measures were the numbers, rates, and proportionate incidence of interval cancers, and rates of total and small (<10 mm) screen detected invasive cancers diagnosed in this cohort of women. Subjects-Women who attended the Scottish breast screening programme (Scottish NHSBSP) from 1 April 1991 to 31 March 1995.
The success of the UK NHS breast screening programme (UK NHSBSP) depends on the provision of a high quality service. A series of performance and quality standards have been established, 1 and routine monitoring and evaluation of performance against these standards is in place. 2 From the outset it has been recognised that a proportion of cancers may not be detected easily by mammography-that is, the sensitivity of screening will be less than 100% and cancers will develop in the intervals between screens. Interval cancer rates have been identified as an important indicator of the eVectiveness of screening as they are related to both the sensitivity of the screening test and to the frequency with which the test is carried out.
The UK NHSBSP standards for interval cancer rates were based on results from the Swedish two counties study 3 and were set by calculating the expected rates after adjustment for the underlying breast cancer incidence in England and Wales. 4 UK programmes have now published interval cancer rates that are in excess of the standards. Two publications presenting data from the North West region and East Anglia programmes suggested diVerent reasons for this: the first that the screening interval was too long, 5 the second that the sensitivity of the screening test was too low and should be improved. 6 The original UK NHSBSP interval cancer standards have been revised, with an increase in the expected numbers. 7 The new standards were derived using an underlying incidence of breast cancer of 21.6 per 10 000 women aged 53-64. Before the introduction of screening, an increasing incidence of breast cancer in England and Wales 8 and Scotland 9 was seen. It is likely that in the absence of screening this trend would have continued. The expected third year rate was also increased after updated data from the Swedish two counties trial showed higher interval rates after a longer follow up period. 7 These two factors have resulted in the revised expected rates being higher than had been assumed in the previous calculations. This paper reports the Scottish interval cancer data from 1 April 1991 to 31 March 1995. During that time the Scottish policy was to screen every three years using single view mammography read by two specially trained screening radiologists. We comment on interval cancer rates, total and small invasive cancer detection rates, and compare the Scottish interval rates with those reported by other programmes. To date, the Scottish third year interval rate is based on only one year's data. For this year, we examine the eVects of using separate expected rates for the age groups 50-54, 55-59, and 60-64 obtained through age-period modelling 10 and calculate the women-years at risk to allow for the fact that not all women remain at risk throughout the full three year period. The women-years at risk have been calculated from each woman's screening history as the days elapsed between the last negative Scottish Cancer Intelligence Unit, Information and Statistics Division, Trinity Park House, South Trinity Road, Edinburgh EH5 3SQ, UK D Everington, statistician C Tyack, statistician screen and the date of rescreening or diagnosis of cancer.
Methods

SUBJECTS
The study population included all women in Scotland aged 50-64 routinely screened between 1 April 1991 and 31 March 1995. The Scottish NHSBSP was phased in from 1988 and was established nationally by 1991. There are seven screening centres in Scotland supported by nine mobile units.
IDENTIFICATION OF INTERVAL CANCERS
Interval cancers are defined in this report as the occurrence of confirmed invasive primary breast cancer within three years of a negative breast screen. Women diagnosed outside the screening programme before the date of an early recall appointment were included, as were women aged 67 or under who presented with breast cancer within three years of their last negative routine screen. Histological verification was obtained in most cases (92.5%) with cytological verification in the remainder.
METHOD OF ASCERTAINMENT
In 1995 interval cancers were identified by linking breast screening data for women screened during the period 1 April 1991 to 31 March 1995, held at the Central Co-ordinating Unit for the Scottish NHSBSP, with registrations of invasive breast cancers from the National Scottish Cancer Register (both data systems are located at the Information and Statistics Division of the National Health Service in Scotland). Medical record linkage is based on probability matching of coded surname, initials, date of birth, and postcode, and achieves matching at a probability level which experience has shown will give acceptable sensitivity and specificity. For this exercise, sensitivity was considered the key factor in minimising any possible underestimation. The results of the linkage are then clerically checked and validated in-house by the record linkage team. Studies of the accuracy of this combined approach indicate a match rate of over 98%. 11 Studies of the National Scottish Cancer Register have shown that the accuracy and validity of the data are comparatively high and that the overall case ascertainment is around 95%. [12] [13] [14] As case ascertainment is less complete for older ages, the ascertainment of breast cancer cases in the age range being studied here is likely to exceed this figure.
Cancers shown by the records to have been screen detected or to have been registered before the first ever oVered appointment were removed from the computer generated list of possible interval cancers. The remaining cases were sent to the screening centres for further checking with recourse to hospital records and pathology reports, as appropriate. From this information cases were excluded from the interval cancer list if classified as screen detected, a non-attender, benign disease, outside the age range 50-64 at last negative screen, or inaccurate registry information. The centres were also asked to add any interval cancers that had been identified locally but were missing from the linkage file. Such cases might arise from a failure to link due to variation in identifying data in the two systems or, for more recent data, by incompleteness in the continuously updated cancer register at the point when the linkage was run.
STATISTICAL METHODS
Underlying incidence is defined as the incidence that would have been observed in the absence of screening. This was estimated from the Scotland age-specific incidence rates for women in the five year age groups 50-54, 55-59, and 60-64 seen in the 10 years before the introduction of screening (1978-87).
Method 1
By fitting a linear trend to the rates, estimates for the age-specific rates in the absence of screening were obtained for the year 1991. These estimated rates were then applied to the age distribution of women screened in 1991, yielding an estimated underlying incidence of 20.3 per 10 000 women aged 50-64. This method could be applied to each of the years 1992-95, yielding slightly higher estimates owing to the increasing trend. However, it was thought preferable to use the more cautious 1991 estimate for all the years rather than extrapolate the trend for a period as long as eight years.
The incidence of interval cancers is expressed as a rate per 10 000 women screened and is also presented as a proportion of the underlying incidence. Ninety five per cent confidence intervals were calculated for the interval cancer and proportionate incidence rates, assuming that the incidence of interval cancers follows a Poisson distribution. This approach has been used in previous publications and has been followed here for consistency and comparability in tables 2-5 . 5 6 15-17 
Method 2
The number of women at risk of developing an interval cancer will decrease over the three year period and therefore interval cancer rates based on the number of women screened are likely to be most accurate in the first year after screening and least accurate in the third year. The reduction in the number of women at risk may be due to women having been diagnosed with either a screen detected or interval cancer, being rescreened before the full three year interval, moving out of the area, or death. From the Scottish NHSBSP screening history recorded for each woman it was possible to identify the time at which each woman was no longer at risk of developing an interval cancer as she had been rescreened or diagnosed with a screen detected or interval cancer. At the time of analysis it was not possible to identify easily the time at which women had died or had moved out of the area. In this method the number of women at risk for each year after screening is adjusted by removing those who have been rescreened or diagnosed with cancer before the year start. Women removed from risk during the first year after the last negative screen are considered to have been at risk for the whole of that first year but not after. Similarly, women removed from risk during the second year after the last negative screen are considered to have been at risk for the first two years but not after. Thus all women contribute one, two, or three years to the women-years at risk.
Method 3
The women-years at risk can be calculated from the person-time elapsed between the date of the last negative screen and the date of rescreening or diagnosis of cancer. If the first of these events occurs after three years the person-time is truncated at three years as we are only considering interval cancer rates up to this time. The women-years at risk for each year after the last negative screen can be obtained by summing the individual womenyears at risk. Methods 1-3 use the same estimate of underlying incidence. Method 1 assumes that all women screened are at risk for a full three year period-that is, the women-years at risk are three years for each woman. Method 2 adjusts the number of women to allow for withdrawals but only at one, two, or three years after the last negative screen-that is, the woman-years at risk are either one, two, or three years. Method 3 calculates the actual time at risk which will be less than that used in method 2. For each of these methods the expected number of cancers is obtained by applying the estimate of underlying incidence to the women-years at risk. The expected number of cancers remains constant for one, two, and three years after a negative screen for method 1 but decreases with time from the last screen for methods 2 and 3. The expected number of cancers will be greatest for method 1 and least for method 3 for each year after a negative screen. As a consequence of this the proportionate incidence rate will be least for method 1 and greatest for method 3.
Methods 4 and 5
A further refinement is to use an age-period Poisson regression model to produce estimates of the expected underlying incidence for each year of screening and for each five year age group (50-54, 55-59, and 60-64). The increasing age of women with time from the last negative screen must be taken into accountthat is, women still at risk at 12-24 months and 24-36 months will have aged by one and two years respectively. The women-years at risk for each age group and each year after the last negative screen can be obtained by summing the appropriate individual women-years at risk. Method 4 uses the same estimates of womenyears at risk as method 2 (adjusted number of women screened), whereas method 5 uses the same estimates as method 3 (actual time at risk). The expected number of cancers can then be obtained by applying each of these estimated rates to the corresponding womenyears at risk for the same screening year and age group. It has been shown that methods 2 and 4 can provide considerably diVerent estimates of the expected numbers of cancers. 10 Calculating the actual time at risk for each year after the last negative screen is more accurate than reducing the number of women screened by those that have been diagnosed with cancer or rescreened before the start of that year. The latter method still assumes that all women at risk at the start of the year remain at risk throughout that year. This assumption is probably greatest in the third year, because for a programme screening at less than three years, the average time at risk in the third year after screening will be less than the full year. The eVect of considering time at risk therefore has the greatest eVect on the third year interval rate. In addition, the current Scottish third year rate is only based on the screening year of 1991-92. We therefore compare estimates produced by these five methods for this year. Current incomplete data are given in italics (below the stepped line). Table 1 shows the number of interval cancers identified by record linkage and the number of additional cases identified by the screening centres. Data are not presented for 1994-95 as the National Scottish Cancer Register was not complete at the time of linkage. To date, a total of 817 interval cancers have been identified in the 390 907 women screened between 1 April 1991 and 31 March 1995. The numbers of interval cancers registered within one, two, and three years of screening were 185, 373, and 259 respectively, though these numbers will increase with further follow up. Table 2 shows the number of interval cancers and the rate with 95% confidence interval by screening year cohort and interval since the last negative screen.
Results
Complete follow up at time of record linkage has elapsed for those figures above the stepped line. Table 2 also shows the invasive cancer and small invasive (<10 mm) cancer detection rates.
All rates in tables 3-5 were calculated from the data in table 2 using only complete datathat is, from above the stepped line. Tables 4  and 5 compare the Scottish interval cancer rates and proportionate incidence with those recently reported from two UK programmes: the North West region 5 and East Anglia, 6 as well as the Nijmegen screening programme 15 and two screening trials: the Swedish two county trial 17 and the Edinburgh randomised trial. 16 The Scottish proportionate incidence rates for the first and second years are very much in line with those published by the North West region and East Anglia. The third year estimate is appreciably lower. Table 6 compares interval cancer and proportionate incidence rates calculated by methods 1-5 for the cohort of women screened in 1991-92 for whom accurate women-years at risk could be calculated (this number is slightly lower than the total number of women screened given in tables 2 and 3). Adjusting the number of women screened to calculate the time at risk resulted in a decrease of 0.6%, 2.0%, and 3.2% in the women-years at risk during the first, second, and third year after screening compared with method 1. Using the actual time at risk resulted in a decrease of 1.2%, 2.8%, and 8.9% in the women-years at risk during the first, second, and third year after screening compared with method 1. The greatest diVerence is seen in the third year rate, particularly when the actual time at risk is used. The two methods of calculating time at risk produce similar estimates for the first and second years after screening (comparing method 2 with 3 and 4 with 5).
Applying the age-period modelled estimates of age-specific rates results in expected rates of 20.3, 20.9, and 21.5 for ages 50-64 for each of the periods 0-12, 12-24, and 24-36 months after the last negative screen (methods 4 and 5). The corresponding rate estimated by linear extrapolation is 20.3 and remains constant with time from the last negative screen. The greatest eVect is again seen on the third year rate. The age-period modelled estimates of the expected rates increase with time from last negative screen because the cohort ages and the rate of breast cancer increases with calendar year. As time from the last negative screen increases, the increasing expected rates and decreasing women-years at risk therefore work against each other. Thus the expected number of cancers estimated by methods 4 and 5 are not substantially diVerent from those obtained by method 1.
From the Scottish NHSBSP screening history it was possible to classify the interval cancer cases by the outcome of the last negative screen, into those that were returned to routine recall, were recalled for assessment, or were put on early recall. Assessment procedures were performed on 16% (121/769) of women screened between 1 April 1991 and 31 March 1994 who subsequently developed an interval cancer. Of these 121 women, 108 were assessed after a routine invitation before being returned to routine recall and 13 were assessed at an early recall invitation, with 10/13 being returned to routine recall and three kept on early recall. Table 7 details the procedures Total 121 *All women have clinical examination at assessment. †Craniocaudal views performed at assessment if not taken at routine screen. These data includes 108 women that were assessed then returned to routine recall, 13 women that were assessed as an early recall appointment with 10 returned to routine recall, and three women kept on early recall. undertaken at assessment. Most of these cases (100) did not undergo an invasive procedure; with only 11 patients having cytology that was either benign or acellular, seven patients having a biopsy, and three being referred to a hospital clinic (procedure unknown).
Discussion
Accurate interval cancer data are essential in order to monitor the performance of a screening programme. Complete data can only be provided from timely recording by a well organised cancer registry with a high ascertainment level. The accuracy and completeness of the National Scottish Cancer Registry and the reliability of record linkage have been established. The process of ascertainment described above should therefore identify virtually all interval cancers. This is reflected by the fact that the screening centres added few cancers to the original cancer registry list (see table 1 ).
A possible problem was identified while ascertaining interval cancer cases. In a small number of cases, women did not attend when the date of oVered appointment was shortly before the date of diagnosis of an interval cancer. If non-attendance resulted from the fact that the process of self referral had already begun, this case should be counted as an interval cancer. However, this can only be determined by a review of individual cases, and has not been undertaken for this report. The Scottish interval cancer rates are in excess of both the original and new UK NHSBSP standards, as has been found in other UK regions. From tables 4 and 5 it can be seen that the interval cancer rates in the first two years after screening are similar to those of the North West region and East Anglia, but the rate in the third year after screening is considerably less. The Scottish results seem inconsistent with previously published interval cancer data that have shown an increase in the rates with time from negative screen, whereas the Scottish third year rate is of the same magnitude as the second year rate.
To further investigate this feature of the data, a women-years at risk analysis was undertaken (table 6). We recommend that other programmes also consider a women-years at risk analysis as the proportion of women still at risk in the third year may diVer from programme to programme. If this is not possible there should be consideration of whether the average screening interval is less or greater than three years. Screening at an interval greater than three years is already happening in the UK in some areas, perhaps owing to an increased workload caused by policy changes in the UK NHSBSP. In this case a comparison could be made month by month. Data on the fourth year rates might also be considered.
Considering the women-years at risk and using an age-period model to estimate the expected rates for each year of screening and for each five year age group did not considerably change our estimates of the expected number of interval cancers (table 6 ). The expected rates estimated for methods 4 and 5 were greater than that used in method 1, but the time at risk is less, resulting in a small net eVect. The diVerence between the expected number of interval cancers calculated using methods 2 and 4 is less than that reported by the North West region. 10 The Scottish ageperiod modelled expected rates were 20.3, 20.9, and 21.5 for ages 50-64 for each of the periods 0-12, 12-24, and 24-36 months after the last negative screen. The estimate of underlying incidence used in methods 1-3 was 20.3 cancers per 10 000 women-years. Therefore, even for the third year after negative screen, the diVerence in estimated expected rates is only of the order of 1 additional cancer per 10 000 women-years at risk. The estimate of 20.3 cancers is based on prescreening data from 1978 to 1987, only four years before 1991. The age-period modelled expected rates will increase with calendar year and therefore later years should show a greater diVerence between estimates obtained by linear extrapolation and those obtained by age-period modelling. The importance of obtaining accurate estimates for the five year age groups will be greater when considering prevalent and incident rounds separately.
Although the third year rate has been increased, it still remains lower than those reported by the North West and East Anglia programmes. However, the third year rate is based on only one year's data, with the following year already showing a higher third year rate before complete follow up has elapsed. Furthermore, the diVerence between the third year rates is not statistically significant. The confidence intervals reported for each of the UK programmes and screening trials for the third year rates are very wide and overlap. Interval cancer data during the early years of the Scottish NHSBSP may also be subject to more variation due to the diVerent learning experience in centres operational for diVerent lengths of time. Additional data would be of interest in order to produce more reliable estimates with narrower confidence intervals. A further record linkage has recently taken place. However, since the process of ascertainment requires a substantial commitment of time from staV in the seven centres and the Central Co-ordinating Unit, the updated results will be reported at a later date.
Other hypotheses explaining the relatively low Scottish third year rate have been suggested. It may be that women in Scotland are less "breast aware" and so are less likely to refer themselves and more likely to be identified at the next screening round or after the three year interval. If they do have symptoms they may be less willing to refer themselves, particularly when they have an impending screening invitation. There is also some evidence to suggest that general practitioners may consider an impending invitation to screening as a more rapid route to a breast surgeon. This eVect might be seen in the incident round screen detected cancers, in the form of higher detection rates with more large cancers than expected. Although the cancer detection rates in the incidence round are relatively high, the cancers tend to be smaller than if this were the case.
Comparison of the UK programme results with those of the screening trials is hindered by variations in the screening regimens, such as the screening interval and age at invitation. The average screening interval for the Swedish two counties trial has been reported as 33 months, whereas it is UK NHSBSP policy to screen every three years. DiVerences in the country of origin and the period of recruitment for diVerent screening populations will impact on the underlying breast cancer incidence.
The high UK interval cancer rates are being addressed. Steps have already been taken to improve the sensitivity of the test after publication of the two view study, which indicated an increased cancer detection rate of the order of 24% compared with single view mammography. 18 Two view mammography was adopted for all women attending their first appointment from July 1995 in Scotland. Analysis of the UK interval cancer rates suggested that screening centres already performing two views on all women showed a corresponding decrease of 25% in interval cancer rates in the first 24 months after screening. Debate continues as to whether this observed improvement in sensitivity of the test is cost eVective.
Sensitivity can also be improved by having two radiologists read the mammograms. Scotland has had a double reading policy since the inception of the programme. The eVect of double reading of mammograms has been variably reported. Warren and DuVy showed that an additional 9.8 cancers per 10 000 screened were detected using this method. 19 In Scotland, an additional 6.6 cancers per 10 000 screened were found. 20 Interval cancers may occur as a result of the radiologist's failure to detect an abnormality at the time of screening (false negative interval cancer) or may develop in the period after a negative mammogram (true interval cancer) with only a small number mammographically occult. Screening radiologists are encouraged to attend courses on small cancer detection to improve their sensitivity and reduce interval cancer rates. Review of interval cancers in Scotland is currently taking place with particular attention being paid to mammographic appearance and pathological features of false negative cancers in an attempt to improve detection rates.
The number of interval cancers which occurred in women who had been assessed was surprisingly high and it is not known whether this is the same in other screening programmes. The 121 interval cancers in this category will be reviewed to determine whether the cancer had been incorrectly assessed or whether the woman had been recalled for a different lesion.
To achieve the 25% reduction in mortality from breast cancer in the screening age group as given in Health of the Nation (Secretary of State for Health, 1992) it is crucial to address the issue of sensitivity of the screening programme. Further data must be accrued to provide evidence which will guide the UK NHSBSP towards the best strategy to improve small cancer detection, and thus reduce interval cancer rates. This should include analysis of data by age, separation of incident and prevalent round cancers, assessment of radiological and pathological features, and examination of the assessment process to avoid misclassification of cancers at the review clinics.
